Diaceutics (LON:DXRX) Stock Rating Reaffirmed by Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX) in a research report report published on Tuesday morning, MarketBeat reports. They currently have a GBX 150 ($1.91) price objective on the stock.

Diaceutics Price Performance

DXRX stock opened at GBX 127.50 ($1.62) on Tuesday. The firm has a 50 day moving average of GBX 105.23 and a 200-day moving average of GBX 97.20. The firm has a market capitalization of £107.65 million, a P/E ratio of 10,500.00 and a beta of 0.47. Diaceutics has a 12 month low of GBX 79 ($1.00) and a 12 month high of GBX 129.53 ($1.65). The company has a current ratio of 7.99, a quick ratio of 9.92 and a debt-to-equity ratio of 3.07.

Insider Activity

In related news, insider Graham Paterson acquired 39,934 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were bought at an average cost of GBX 129 ($1.64) per share, for a total transaction of £51,514.86 ($65,473.89). In other Diaceutics news, insider Peter Keeling sold 750,000 shares of Diaceutics stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of GBX 102 ($1.30), for a total transaction of £765,000 ($972,292.83). Also, insider Graham Paterson acquired 39,934 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was purchased at an average price of GBX 129 ($1.64) per share, with a total value of £51,514.86 ($65,473.89). Company insiders own 34.54% of the company’s stock.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.